Prior aspirin use and outcomes in acute coronary syndromes

Journal of the American College of Cardiology

Volumn 56, Issue 17, 2010, Pages 1376-1385

  Rich, Jonathan D ^a   Cannon, Christopher P ^b   Murphy, Sabina A ^b   Qin, Jie ^b   Giugliano, Robert P ^b   Braunwald, Eugene ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

acute coronary syndromes; aspirin; myocardial infarction; prognosis; risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PRAVASTATIN; TENECTEPLASE; TIROFIBAN; WARFARIN; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTICLE; BLOOD CLOT LYSIS; CORONARY RISK; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; RECURRENT DISEASE; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; ANGIOCARDIOGRAPHY; CORONARY DISEASE; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; RADIOGRAPHY; RISK FACTOR; SURVIVAL RATE;

ACUTE CORONARY SYNDROME; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY DISEASE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SURVIVAL RATE; KAPLAN-MEIER ESTIMATE;

EID: 77957926257     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.06.028     Document Type: Article

References (42)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 2 1988 349 360
2. Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study N Engl J Med 321 1989 129 135
3. The RISC Group Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease Lancet 336 1990 827 830
4. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy: I Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
5. J.A. Cairns, M. Gent, and J. Singer Aspirin, sulfinpyrazone, or both in unstable angina Results of a Canadian multicenter trial N Engl J Med 313 1985 1369 1375
6. H.D. Lewis Jr., J.W. Davis, and D.G. Archibald Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina Results of a Veterans Administration Cooperative Study N Engl J Med 309 1983 396 403
7. V. Fuster, L. Badimon, J.J. Badimon, and J.H. Chesebro The pathogenesis of coronary artery disease and the acute coronary syndromes (2) N Engl J Med 326 1992 310 318
8. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
9. J.H. Alexander, R.A. Harrington, R.H. Tuttle PURSUIT Investigators Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy Am J Cardiol 83 1999 1147 1151
10. G.I. Lancaster, C.J. Lancaster, D. Radley, and M. Cohen Prior aspirin use in unstable angina predisposes to higher risk: the aspirin paradox Int J Cardiol 80 2001 201 207
11. J. Santopinto, E.P. Gurfinkel, and V. Torres Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin Am Heart J 141 2001 566 572
12. J.W. Eikelboom, J. Hirsh, J.I. Weitz, M. Johnston, Q. Yi, and S. Yusuf Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 105 2002 1650 1655
13. P.A. Gum, K. Kottke-Marchant, P.A. Welsh, J. White, and E.J. Topol A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 2003 961 965
14. The TIMI IIIB Investigators Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction Results of the TIMI IIIB Trial Circulation 89 1994 1545 1556
15. The InTIME-II Investigators Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs. accelerated alteplase for the treatment of patients with acute myocardial infarction Eur Heart J 21 2000 2005 2013
16. E.M. Antman, R.P. Giugliano, C.M. Gibson TIMI 14 Investigators Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial Circulation 99 1999 2720 2732
17. E.M. Antman, H.W. Louwerenburg, and H.F. Baars Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial Circulation 105 2002 1642 1649
18. E.M. Antman, D.A. Morrow, and C.H. McCabe Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction N Engl J Med 354 2006 1477 1488
19. M.A. Blazing, J.A. de Lemos, and H.D. White Safety and efficacy of enoxaparin vs. unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial JAMA 292 2004 55 64
20. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
21. C.P. Cannon, C.M. Gibson, C.H. McCabe Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial Circulation 98 1998 2805 2814
22. C.P. Cannon, C.H. McCabe, and D.J. Diver Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial J Am Coll Cardiol 24 1994 1602 1610
23. C.P. Cannon, C.H. McCabe, and C.M. Gibson TNK-tissue plasminogen activator in acute myocardial infarction Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial Circulation 95 1997 351 356
24. C.P. Cannon, C.H. McCabe, and R.G. Wilcox Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial Circulation 102 2000 149 156
25. C.P. Cannon, W.S. Weintraub, and L.A. Demopoulos Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban N Engl J Med 344 2001 1879 1887
26. R.P. Giugliano, M.T. Roe, and R.A. Harrington Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the Integrilin and Tenecteplase in Acute Myocardial Infarction (INTEGRITI) phase II angiographic trial J Am Coll Cardiol 41 2003 1251 1260
27. E.M. Ohman, F. Van de Werf, and E.M. Antman Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial Am Heart J 150 2005 79 88
28. M.S. Sabatine, C.P. Cannon, and C.M. Gibson Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189
29. S.D. Wiviott, E.M. Antman, and K.J. Winters Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial Circulation 111 2005 3366 3373
30. J.A. de Lemos, M.A. Blazing, and S.D. Wiviott Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
31. E.M. Antman, M. Cohen, and P.J. Bernink The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making JAMA 284 2000 835 842
32. D.A. Morrow, E.M. Antman, and A. Charlesworth TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy Circulation 102 2000 2031 2037
33. F.A. Spencer, J.J. Santopinto, and J.M. Gore Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (The Global Registry of Acute Coronary Events [GRACE]) Am J Cardiol 90 2002 1056 1061
34. E.L. Portnay, J.M. Foody, and S.S. Rathore Prior aspirin use and outcomes in elderly patients hospitalized with acute myocardial infarction J Am Coll Cardiol 46 2005 967 974
35. R.L. Soiza, and S.J. Leslie Prior clopidogrel use and outcome of acute coronary syndrome Int J Cardiol 111 2006 313 314
36. S. Borzak, C.P. Cannon, P.L. Kraft TIMI 7 Investigators Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina Thrombin Inhibition in Myocardial Ischemia Am J Cardiol 81 1998 678 681
37. N.F. Col, J. Yarzbski, J.M. Gore, J.S. Alpert, and R.J. Goldberg Does aspirin consumption affect the presentation or severity of acute myocardial infarction? Arch Intern Med 155 1995 1386 1389
38. D. Garcia-Dorado, P. Theroux, and P. Tornos Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes Circulation 92 1995 1743 1748
39. H.L. Dauerman, D. Lessard, J. Yarzebski, M.I. Furman, J.M. Gore, and R.J. Goldberg Ten-year trends in the incidence, treatment, and outcome of Q-wave myocardial infarction Am J Cardiol 86 2000 730 735
40. W. Rosamond, K. Flegal, and K. Furie Heart Disease and Stroke Statistics2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 117 2007 e25 e146
41. X. Cheng, W.H. Chen, and D.I. Simon Aspirin resistance or variable response or both? Am J Cardiol 98 2006 11N 17N
42. A.L. Frelinger 3rd, M.I. Furman, and M.D. Linden Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance Circulation 113 2006 2888 2896